1
|
Microbial isoprenoid biosynthesis and human gammadelta T cell activation.
|
FEBS Lett
|
2003
|
2.30
|
2
|
Fosmidomycin for malaria.
|
Lancet
|
2002
|
2.03
|
3
|
The interplay between classical and alternative isoprenoid biosynthesis controls gammadelta T cell bioactivity of Listeria monocytogenes.
|
FEBS Lett
|
2004
|
1.93
|
4
|
New antimalarial drugs.
|
Angew Chem Int Ed Engl
|
2003
|
1.68
|
5
|
In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.
|
Antimicrob Agents Chemother
|
2002
|
1.65
|
6
|
RlmN and Cfr are radical SAM enzymes involved in methylation of ribosomal RNA.
|
J Am Chem Soc
|
2010
|
1.60
|
7
|
Structure of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway.
|
J Am Chem Soc
|
2008
|
1.57
|
8
|
LytB protein catalyzes the terminal step of the 2-C-methyl-D-erythritol-4-phosphate pathway of isoprenoid biosynthesis.
|
FEBS Lett
|
2002
|
1.55
|
9
|
Fosmidomycin, a novel chemotherapeutic agent for malaria.
|
Antimicrob Agents Chemother
|
2003
|
1.46
|
10
|
Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy.
|
J Immunol
|
2007
|
1.42
|
11
|
Fosmidomycin for the treatment of malaria.
|
Parasitol Res
|
2002
|
1.40
|
12
|
Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria.
|
Antimicrob Agents Chemother
|
2006
|
1.35
|
13
|
Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children.
|
J Infect Dis
|
2004
|
1.35
|
14
|
Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria.
|
J Infect Dis
|
2004
|
1.34
|
15
|
Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques.
|
J Immunol
|
2007
|
1.32
|
16
|
The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum.
|
J Biol Chem
|
2004
|
1.31
|
17
|
Functional characterization of GcpE, an essential enzyme of the non-mevalonate pathway of isoprenoid biosynthesis.
|
FEBS Lett
|
2002
|
1.17
|
18
|
Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells.
|
J Leukoc Biol
|
2006
|
1.08
|
19
|
Differentiation of human gamma-delta T cells towards distinct memory phenotypes.
|
Cell Immunol
|
2002
|
1.07
|
20
|
Antigen-specific Vgamma2Vdelta2 T effector cells confer homeostatic protection against pneumonic plaque lesions.
|
Proc Natl Acad Sci U S A
|
2009
|
1.05
|
21
|
Crystal structure of 1-deoxy-D-xylulose-5-phosphate reductoisomerase, a crucial enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.
|
J Biol Chem
|
2001
|
1.05
|
22
|
Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways.
|
PLoS One
|
2011
|
1.04
|
23
|
Double ester prodrugs of FR900098 display enhanced in-vitro antimalarial activity.
|
Arch Pharm (Weinheim)
|
2007
|
1.03
|
24
|
Isoprenoid biosynthesis of the apicoplast as drug target.
|
Curr Drug Targets
|
2007
|
1.03
|
25
|
Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors.
|
Bioorg Med Chem Lett
|
2006
|
1.03
|
26
|
Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates.
|
PLoS Pathog
|
2013
|
1.02
|
27
|
The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally regulated by Dxs.
|
J Bacteriol
|
2010
|
1.02
|
28
|
Human Vgamma9/Vdelta2 effector memory T cells express the killer cell lectin-like receptor G1 (KLRG1).
|
J Leukoc Biol
|
2004
|
1.02
|
29
|
Reconstitution of an apicoplast-localised electron transfer pathway involved in the isoprenoid biosynthesis of Plasmodium falciparum.
|
FEBS Lett
|
2005
|
1.00
|
30
|
Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.
|
Bioorg Med Chem
|
2007
|
1.00
|
31
|
Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits.
|
J Immunol
|
2009
|
0.99
|
32
|
Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.
|
Antimicrob Agents Chemother
|
2005
|
0.99
|
33
|
Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo.
|
Angew Chem Int Ed Engl
|
2004
|
0.98
|
34
|
Accumulation of a potent gammadelta T-cell stimulator after deletion of the lytB gene in Escherichia coli.
|
Immunology
|
2002
|
0.98
|
35
|
Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase complexes.
|
J Am Chem Soc
|
2004
|
0.97
|
36
|
Possible direct involvement of the active-site [4Fe-4S] cluster of the GcpE enzyme from Thermus thermophilus in the conversion of MEcPP.
|
FEBS Lett
|
2006
|
0.97
|
37
|
Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues.
|
Arch Pharm (Weinheim)
|
2007
|
0.96
|
38
|
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
|
Bioorg Med Chem Lett
|
2002
|
0.95
|
39
|
Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity.
|
Bioorg Med Chem Lett
|
2003
|
0.94
|
40
|
Paramagnetic intermediates of (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase (GcpE/IspG) under steady-state and pre-steady-state conditions.
|
J Am Chem Soc
|
2010
|
0.94
|
41
|
Structure of the E-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate synthase (GcpE) from Thermus thermophilus.
|
FEBS Lett
|
2010
|
0.94
|
42
|
Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro.
|
Int J Parasitol
|
2006
|
0.93
|
43
|
Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism.
|
Bioorg Med Chem Lett
|
2003
|
0.93
|
44
|
Towards new antimalarial drugs: synthesis of non-hydrolyzable phosphate mimics as feed for a predictive QSAR study on 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors.
|
Chem Biodivers
|
2008
|
0.91
|
45
|
Synthesis of analogues of (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate, an isoprenoid precursor and human gamma delta T cell activator.
|
J Org Chem
|
2008
|
0.90
|
46
|
Mycoplasma penetrans is capable of activating V gamma 9/V delta 2 T cells while other human pathogenic mycoplasmas fail to do so.
|
Infect Immun
|
2004
|
0.87
|
47
|
Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity.
|
Arch Pharm (Weinheim)
|
2005
|
0.86
|
48
|
Divergent strategy for the synthesis of alpha-aryl-substituted fosmidomycin analogues.
|
J Org Chem
|
2007
|
0.86
|
49
|
Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors.
|
Bioorg Med Chem Lett
|
2007
|
0.86
|
50
|
Antimalarial activity of n(6)-substituted adenosine derivatives (part 2).
|
J Comb Chem
|
2002
|
0.85
|
51
|
Analysis of the isoprenoid biosynthesis pathways in Listeria monocytogenes reveals a role for the alternative 2-C-methyl-D-erythritol 4-phosphate pathway in murine infection.
|
Infect Immun
|
2008
|
0.85
|
52
|
Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors.
|
J Med Chem
|
2006
|
0.82
|
53
|
Studies addressing the importance of charge in the binding of fosmidomycin-like molecules to deoxyxylulosephosphate reductoisomerase.
|
ChemMedChem
|
2008
|
0.82
|
54
|
Synthesis of the antimalarial drug FR900098 utilizing the nitroso-ene reaction.
|
Org Lett
|
2007
|
0.81
|
55
|
Structure of the (E)-4-hydroxy-3-methyl-but-2-enyl-diphosphate reductase from Plasmodium falciparum.
|
FEBS Lett
|
2013
|
0.81
|
56
|
Structure of the GcpE (IspG)-MEcPP complex from Thermus thermophilus.
|
FEBS Lett
|
2012
|
0.81
|
57
|
Anti-malarial activity of N(6)-substituted adenosine derivatives. Part I.
|
Bioorg Med Chem
|
2002
|
0.81
|
58
|
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
|
Bioorg Med Chem Lett
|
2003
|
0.79
|
59
|
Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity.
|
Eur J Med Chem
|
2005
|
0.79
|
60
|
Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells.
|
Immunology
|
2004
|
0.79
|
61
|
Primary MHC-class II(+) cells are necessary to promote resting Vδ2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and isopentenyl pyrophosphate.
|
J Immunol
|
2012
|
0.79
|
62
|
Determination of fosmidomycin in human serum and urine by capillary electrophoresis.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2004
|
0.78
|
63
|
Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
|
Immunology
|
2006
|
0.78
|
64
|
Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials.
|
ChemMedChem
|
2008
|
0.77
|
65
|
Antimalarial activity of N(6)-substituted adenosine derivatives. Part 3.
|
Bioorg Med Chem
|
2004
|
0.77
|
66
|
A genetic basis for human gammadelta T-cell reactivity towards microbial pathogens.
|
Trends Immunol
|
2003
|
0.76
|
67
|
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
|
Bioorg Med Chem Lett
|
2003
|
0.75
|
68
|
Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides.
|
Bioorg Med Chem Lett
|
2002
|
0.75
|
69
|
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.
|
Bioorg Med Chem Lett
|
2003
|
0.75
|
70
|
NMR studies of DOXP reductoisomerase and its inhibitor complex.
|
Chembiochem
|
2011
|
0.75
|